Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. It blocks viral entry into host cells while preserving normal immunologic function. The Company is also investigating an intramuscular method of administration of Trogarzo. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy.


TSX:TH - Post by User

Comment by Bucknelly21on Jan 04, 2023 9:28pm
103 Views
Post# 35204045

RE:Lottery ticket

RE:Lottery ticketYou have said about five times pauls next move will define his legacy lol
palinc2000 wrote: The first draw of the Lottery Ticket bought by previoys  management was drawn at the beginning of December was not a winning ticket...Admittedly the potential benifit appeared to be very high compared to the low purchase cost of the lottery ticket when our former Ceo bought Katana.... Recall that Katana had tried to find a Buyer for over a year with no takers!!!So what appeared to be low acquisition cost turned out to be a major distraction which also involved millions $ in pre clinical and clinical costs and which compounded the negative impact of the Company opting to issue a Convetrt instead of issuing Stock at 11usd or 14 Cad .BTW the dark cloud of the Convert is still there and the recent Finanving only allows to kick part of the can down the road.

I said afer the Pause that Paul's next move will determine his Legacy.... I really like how he described  the path forward  but still want to see if he will want to own the go path in oncology 

The decision to buy Katana and improvise as an oncology company was apparently made by the former Ceo with no experts weighing in .... The current CEO will at least rely on knowledgeable oncology experts before determining the path forward for the Sort 1 platform and I trust it will be a rational decidion and not to create a distraction!!!
One cannot exclude a change in the C Suite in line with the New Mission


<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse